National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Events (1)
- (-) Arthritis (38)
- Back Health and Pain (1)
- Cancer (1)
- Cancer: Breast Cancer (1)
- Care Management (1)
- Children/Adolescents (2)
- Chronic Conditions (3)
- Clinical Decision Support (CDS) (1)
- Comparative Effectiveness (9)
- Decision Making (1)
- Digestive Disease and Health (1)
- Education (1)
- Elderly (2)
- Electronic Health Records (EHRs) (1)
- Evidence-Based Practice (6)
- Guidelines (1)
- Healthcare-Associated Infections (HAIs) (1)
- Healthcare Costs (1)
- Health Information Technology (HIT) (4)
- Injuries and Wounds (2)
- Learning Health Systems (1)
- Low-Income (1)
- Medicare (1)
- Medication (8)
- Mortality (1)
- Obesity (1)
- Obesity: Weight Management (1)
- Opioids (1)
- Orthopedics (5)
- Osteoporosis (1)
- Outcomes (6)
- Pain (7)
- (-) Patient-Centered Outcomes Research (38)
- Patient Safety (2)
- Practice Patterns (1)
- Quality of Care (1)
- Quality of Life (1)
- Racial and Ethnic Minorities (2)
- Registries (8)
- Research Methodologies (2)
- Risk (2)
- Social Determinants of Health (2)
- Surgery (12)
- Treatments (3)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
26 to 38 of 38 Research Studies DisplayedChristensen R, Maxwell LJ, Juni P
Consensus on the need for a hierarchical list of patient-reported pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective.
A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for metaanalyses. After discussions, most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome measurement instruments to guide metaanalyses.
AHRQ-funded; HS021110.
Citation: Christensen R, Maxwell LJ, Juni P .
Consensus on the need for a hierarchical list of patient-reported pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective.
J Rheumatol 2015 Oct;42(10):1971-75. doi: 10.3899/jrheum.141384..
Keywords: Research Methodologies, Arthritis, Pain, Patient-Centered Outcomes Research
Busse JW, Bartlett SJ, Dougados M
Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 Workshop.
A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for metaanalyses. After discussions, most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome measurement instruments to guide metaanalyses.
AHRQ-funded; HS021110.
Citation: Busse JW, Bartlett SJ, Dougados M .
Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 Workshop.
J Rheumatol 2015 Oct;42(10):1962-70. doi: 10.3899/jrheum.141440..
Keywords: Patient-Centered Outcomes Research, Arthritis, Research Methodologies, Pain
Singh JA, Cameron C, Noorbaloochi S
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
The researchers sought to determine whether biological drugs are associated with an increased risk of serious infection compared with traditional disease-modifying antirheumatic drugs (DMARDs). They found that standard-dose and high-dose biological drugs, with or without traditional DMARDs, are associated with an increase in serious infections in rheumatoid arthritis compared with traditional DMARDs, although low-dose biological drugs are not.
AHRQ-funded; HS021110.
Citation: Singh JA, Cameron C, Noorbaloochi S .
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Lancet 2015 Jul 18;386(9990):258-65. doi: 10.1016/s0140-6736(14)61704-9.
.
.
Keywords: Comparative Effectiveness, Medication, Arthritis, Patient-Centered Outcomes Research
LoVerde ZJ, Mandl LA, Johnson BK
Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study.
More adverse events (AE) are reported after total knee arthroplasty (TKA) for patients with rheumatoid arthritis (RA) than for patients with osteoarthritis (OA). This study evaluates 6-month postoperative AE in a high-volume center in a contemporary RA cohort. It found that in a high-volume center, with high RA-specific experience, RA does not increase postoperative AE.
AHRQ-funded; HS016075.
Citation: LoVerde ZJ, Mandl LA, Johnson BK .
Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study.
J Rheumatol 2015 Jul;42(7):1123-30. doi: 10.3899/jrheum.141251..
Keywords: Adverse Events, Arthritis, Surgery, Comparative Effectiveness, Patient-Centered Outcomes Research
Kavanaugh A, Lee SJ, Curtis JR
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
There is increasing interest in discontinuing biological therapies for patients with rheumatoid arthritis achieving good clinical responses, provided patients maintain clinical benefit. Using data from the Corrona registry, the investigators found that discontinuation of a first course of tumour necrosis factor inhibitor may be associated with persistent clinical benefit. Half of the registry patients included in the study maintained response through 20 months.
AHRQ-funded; HS018517.
Citation: Kavanaugh A, Lee SJ, Curtis JR .
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Ann Rheum Dis 2015 Jun;74(6):1150-5. doi: 10.1136/annrheumdis-2014-206435.
.
.
Keywords: Medication, Patient-Centered Outcomes Research, Registries, Arthritis
Yun H, Xie F, Delzell E
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
The researchers compare the subsequent risk of hospitalized infections associated with specific biologic agents among RA patients previously hospitalized for infection while receiving anti-tumor necrosis factor (anti-TNF) therapy. They found that among rheumatoid arthritis patients who experienced a hospitalized infection while on anti-TNF therapy, abatacept and etanercept were associated with the lowest risk of a subsequent infection compared to other biologic therapies.
AHRQ-funded; HS021694; HS023009; HS018517.
Citation: Yun H, Xie F, Delzell E .
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Ann Rheum Dis 2015 Jun;74(6):1065-71. doi: 10.1136/annrheumdis-2013-204011..
Keywords: Arthritis, Healthcare-Associated Infections (HAIs), Healthcare-Associated Infections (HAIs), Patient-Centered Outcomes Research, Patient Safety
Zhang J, Xie F, Delzell E
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
The purpose of this study was to examine whether concomitant methotrexate (MTX) use is associated with better biologic persistence and whether self-administered anti–tumor necrosis factor (anti-TNF) therapies are used at reduced doses in real world clinical care settings, not just clinical trials. It found that use of concomitant MTX is associated with greater persistence to biologic therapy.
AHRQ-funded; HS018517.
Citation: Zhang J, Xie F, Delzell E .
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Arthritis Care Res 2015 May;67(5):624-32. doi: 10.1002/acr.22510..
Keywords: Arthritis, Comparative Effectiveness, Patient-Centered Outcomes Research, Treatments
Yun H, Xie F, Delzell E
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
This study evaluated whether the risks of herpes zoster (HZ) differed by biologic agents with different mechanisms of action (MOAs) in older rheumatoid arthritis (RA) patients. Using Medicare data from 2006–2011, the researchers found that among RA patients, the rate and adjusted hazard ratios of HZ were similar among biologic agents, including those with non–tumor necrosis factor mechanisms of action.
AHRQ-funded; HS021694; HS018517.
Citation: Yun H, Xie F, Delzell E .
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Arthritis Care Res 2015 May;67(5):731-6. doi: 10.1002/acr.22470..
Keywords: Arthritis, Risk, Patient Safety, Patient-Centered Outcomes Research
Newman ED, Lerch V, Billet J
Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software.
To improve the quality of care for patients with rheumatic disease, the researchers developed electronic data capture, aggregation, display, and documentation software. They found that their software was adopted for use by 86% of patients and rheumatologists. They concluded that the software was well-adopted by patients and providers. Post-implementation, significant improvements in quality of care, efficiency of care, and productivity were demonstrated.
AHRQ-funded; 290200600019I.
Citation: Newman ED, Lerch V, Billet J .
Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software.
Arthritis Care Res 2015 Apr;67(4):546-53. doi: 10.1002/acr.22479..
Keywords: Health Information Technology (HIT), Quality of Care, Arthritis, Patient-Centered Outcomes Research
Harrold LR, Reed GW, Kremer JM
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
The investigators compared the effectiveness of abatacept (ABA) versus a subsequent anti-tumour necrosis factor inhibitor (anti-TNF) in rheumatoid arthritis (RA) patients with prior anti-TNF use. They found that RA patients with prior anti-TNF exposures had similar outcomes if they switched to a new anti-TNF as compared with initiation of ABA.
AHRQ-funded; HS018517.
Citation: Harrold LR, Reed GW, Kremer JM .
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
Ann Rheum Dis 2015 Feb;74(2):430-6. doi: 10.1136/annrheumdis-2013-203936.
.
.
Keywords: Comparative Effectiveness, Medication, Patient-Centered Outcomes Research, Arthritis
Mannion ML, Xie F, Curtis JR
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
The researchers investigated temporal trends in medication use among children diagnosed with juvenile idiopathic arthritis (JIA). They found that the use of tumor necrosis factor inhibitors (TNFi) in the treatment of JIA increased 2- to 3-fold from 2005 to 2012. New TNFi use was associated with decreased NSAID and oral glucocorticoids use. TNFi may be replacing, rather than complementing, methotrexate in the treatment of many patients.
AHRQ-funded; HS018517.
Citation: Mannion ML, Xie F, Curtis JR .
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
J Rheumatol 2014 Oct;41(10):2078-84. doi: 10.3899/jrheum.140012.
.
.
Keywords: Children/Adolescents, Medication, Patient-Centered Outcomes Research, Practice Patterns, Arthritis
Ayers DC, Franklin PD
Joint replacement registries in the United States: a new paradigm.
This commentary serves as an introduction to an upcoming series of articles about orthopaedic registries, in general, with an emphasis on lessons learned from the evolving U.S. and international total joint replacement registries. Specifically, this paper provides an overview of total joint replacement registries and the current expansion of data collection beyond implant attributes and survival to include postoperative complications and patient-reported outcomes.
AHRQ-funded; HS018910.
Citation: Ayers DC, Franklin PD .
Joint replacement registries in the United States: a new paradigm.
J Bone Joint Surg Am 2014 Sep 17;96(18):1567-9. doi: 10.2106/jbjs.n.00641.
.
.
Keywords: Arthritis, Chronic Conditions, Patient-Centered Outcomes Research, Registries, Surgery
Ayers DC, Franklin PD
Joint replacement registries in the United States: a new paradigm.
This commentary serves as an introduction to an upcoming series of articles about orthopaedic registries, in general, with an emphasis on lessons learned from the evolving U.S. and international total joint replacement registries. Specifically, this paper provides an overview of total joint replacement registries and the current expansion of data collection beyond implant attributes and survival to include postoperative complications and patient-reported outcomes.
AHRQ-funded; HS018910.
Citation: Ayers DC, Franklin PD .
Joint replacement registries in the United States: a new paradigm.
J Bone Joint Surg Am 2014 Sep 17;96(18):1567-9. doi: 10.2106/jbjs.n.00641..
Keywords: Arthritis, Chronic Conditions, Patient-Centered Outcomes Research, Registries, Surgery